Overview
TB-500 is a synthetic version of the 17-amino-acid active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually every mammalian cell. Tβ4 is one of the most abundant peptides in the human body — with particularly high concentrations in platelets, white blood cells, and sites of tissue injury — and plays a central role in wound healing, tissue repair, and inflammation modulation.
The “TB-500” name refers to the specific actin-binding region of Tβ4 (amino acids 17–23, LKKTET sequence) that is believed to be responsible for the majority of Tβ4’s regenerative effects. By sequestering G-actin (monomeric actin), this fragment regulates cell structure, motility, and the formation of new blood vessels.
TB-500 is widely used in research settings and has gained significant popularity in the athletic and biohacking communities for its reported effects on injury recovery, though it has no approved human applications.
Mechanism of Action
Actin Sequestration: TB-500’s primary molecular action is binding to G-actin, preventing its polymerization into F-actin filaments. This regulatory control over actin dynamics is fundamental to cell migration — a critical step in wound healing.
Cell Migration: By modulating actin dynamics, TB-500 promotes directed migration of endothelial cells, keratinocytes, and fibroblasts toward injury sites — the foundational step in tissue regeneration.
Angiogenesis: TB-500 stimulates the formation of new blood vessels (angiogenesis) in ischemic and injured tissue, improving oxygen and nutrient delivery to healing areas.
Anti-inflammatory: Inhibits inflammatory cytokines, particularly via downregulation of NF-κB signaling, while preserving the initial inflammatory phase necessary for proper healing.
Cardiac Protection: Several studies have explored Tβ4’s cardiac applications — promoting cardiomyocyte survival and potentially reactivating dormant cardiac progenitor cells post-infarction.
Clinical Research & Evidence
Evidence Level: 🟠 EL3 — Strong animal data, very limited human data
| Study Focus | Model | Findings |
|---|---|---|
| Cardiac repair | Mouse | Tβ4 mobilized cardiac stem cells after MI; improved ejection fraction |
| Tendon healing | Rat | Accelerated tendon repair vs. control; improved collagen organization |
| Corneal healing | Rabbit | Faster epithelial closure; approved eye drop study |
| Skin healing | Human (Phase II) | PF-02545920 (Tβ4-based) showed improved wound closure in venous ulcers |
| Neurological | Rat | Promoted oligodendrocyte differentiation; potential MS application |
Notable human study: RegeneRx Biopharmaceuticals conducted Phase I/II trials of Tβ4 for wound healing and ophthalmic applications. Phase II results showed tolerability and early efficacy signals, but programs were not advanced to Phase III.
Research-Referenced Dosing Protocols
Animal-derived data only. No validated human dosing exists.
- Research cycle: Typically 10–20 mg/week split into 2–3 injections
- Common protocol: 5–7.5 mg subcutaneous injection 2–3x/week for 4–6 weeks
- Often stacked with BPC-157 for synergistic tissue repair effect (different mechanisms)
Side Effects & Contraindications
Animal studies: No significant toxicity at therapeutic doses. Well-tolerated in rodent and canine models.
Anecdotal human reports:
- Fatigue/lethargy (common at initiation)
- Head rush/dizziness shortly after injection
- Potential exacerbation of existing tumors (theoretical — pro-angiogenic mechanism)
Contraindications (theoretical):
- Active malignancy
- Pregnancy
Legal & Regulatory Status
| Region | Status |
|---|---|
| United States | No FDA approval; research chemical status. Previously compoundable under 503A; current status requires verification with current FDA guidance. |
| European Union | No EMA approval; available as research chemical |
| Australia | Prohibited in competition by WADA; not TGA approved |
| WADA | Prohibited in sport (S2 — Peptide Hormones, Growth Factors) |
Research Citations
- Goldstein AL, et al. Thymosin β4: A multi-functional regenerative peptide. Expert Opin Biol Ther. 2012.
- Smart N, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007.
- Huff T, et al. The Cβ4 peptide: structural and functional implications of a novel actin-binding mechanism. FASEB J. 2004.
- Philp D, et al. Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004.
- Sosne G, et al. Thymosin beta 4 promotes corneal wound healing. Exp Eye Res. 2002.